DaVita Inc. $DVA Shares Acquired by ING Groep NV

ING Groep NV grew its position in DaVita Inc. (NYSE:DVA) by 418.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,321 shares of the company’s stock after buying an additional 10,753 shares during the quarter. ING Groep NV’s holdings in DaVita were worth $1,513,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also modified their holdings of the company. Elevation Wealth Partners LLC grew its stake in shares of DaVita by 147.3% in the fourth quarter. Elevation Wealth Partners LLC now owns 277 shares of the company’s stock valued at $31,000 after buying an additional 165 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of DaVita in the second quarter valued at $43,000. iSAM Funds UK Ltd acquired a new stake in shares of DaVita in the third quarter valued at $46,000. Stance Capital LLC acquired a new position in DaVita during the 3rd quarter worth $47,000. Finally, Fideuram Asset Management Ireland dac acquired a new position in DaVita during the 4th quarter worth $49,000. 90.12% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at DaVita

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of DaVita stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the sale, the chief financial officer directly owned 132,434 shares of the company’s stock, valued at $25,440,571.40. The trade was a 27.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.50% of the stock is owned by company insiders.

DaVita Price Performance

Shares of NYSE DVA opened at $198.19 on Wednesday. The company has a market capitalization of $12.72 billion, a price-to-earnings ratio of 18.39, a price-to-earnings-growth ratio of 0.63 and a beta of 0.91. The business has a 50-day moving average of $173.05 and a two-hundred day moving average of $144.47. DaVita Inc. has a 1 year low of $101.00 and a 1 year high of $202.69.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. The company had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.DaVita’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same period in the previous year, the business earned $2.00 EPS. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities research analysts expect that DaVita Inc. will post 15.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on DVA shares. TD Cowen boosted their target price on DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research note on Monday, May 11th. Truist Financial boosted their target price on DaVita from $158.00 to $205.00 and gave the stock a “hold” rating in a research note on Friday, May 8th. Barclays boosted their target price on DaVita from $158.00 to $194.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 7th. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Finally, UBS Group boosted their target price on DaVita from $190.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $199.17.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.